Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof
CA 2337083 A1 · Owner: Massie, Bernard · Inventors: Langelier, Yves; Massie, Bernard
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The R1 subunit of herpes simplex virus (HSV) ribonucleotide reductase which , is expressed very early after viral reactivation possesses an N-terminal , domain of about 350 amino acids of unknown function. Using an adenovirus (Ad) inducible system we had demonstrated that a complete deletion of this domain produces a cytotoxic protein. We now report that apoptotic death induced by this truncated R1 could be completely prevented by coexpression of the fulllength R1. The R1 antiapoptotic activity was further substantiated by showing that expression of this protein at low level can completely block apoptosis induced either by TNF-receptor family triggering in the presence of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 23, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 23, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 23, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.